MONTRÉAL, Jan. 07, 2021 (GLOBE NEWSWIRE) -- ExCellThera Inc., a clinical-stage molecular medicine company delivering molecules and bioengineering solutions to expand stem and immune cells for therapeutic use, announced today the publication of new data describing the mechanism of action of UM171, the proprietary molecule which forms the basis of ECT-001 Cell Therapy.
Visit link:
ExCellThera announces UM171 mechanism of action
Related Post
- PCI Biotech to present at RNA Therapeutics Virtual Conference - January 24th, 2021
- Mydecine Innovations Group Included in First-Ever Psychedelics ETF - January 24th, 2021
- BioCryst Announces Approval of ORLADEYO™ (berotralstat) in Japan for the Prophylactic Treatment of Hereditary Angioedema - January 24th, 2021
- Equillium Announces Acceptance of Late-Breaking Abstract for Oral Presentation of Interim Data from EQUATE Study in acute GVHD at the 2021 TCT... - January 24th, 2021
- aTyr Pharma to Present Poster Highlighting Research Approach for Identifying Receptor Targets for Extracellular tRNA Synthetases - January 24th, 2021
- Report from the Extraordinary General Meeting of Immunicum AB (publ) on 22 January 2021 - January 24th, 2021
- Teligent Regains Compliance with Nasdaq Filing Requirements and Nasdaq Minimum Market Value Rule - January 24th, 2021
- Albireo Recognizes International Alagille Syndrome Awareness Day 2021 - January 24th, 2021
- Ten Leading BioPharma Companies Announce Formation of Accumulus Synergy to Develop Global Data Sharing Platform - January 24th, 2021
- Revive Therapeutics Included in First Psychedelic Exchange Traded Fund - January 24th, 2021
- Cambium Networks Corporation Announces Fourth Quarter and Full Year 2020 Reporting Date - January 24th, 2021
- Bioasis Announces Stock Option Grant - January 24th, 2021
- Zealand Pharma announces update to 2020 financial guidance - January 24th, 2021
- Novavax Names Madelyn Caltabiano Senior Vice President, Global Program Management - January 24th, 2021
- Blood Sugar Premier – Does This Supplement Really Works? Ingredients & Blood Sugar Premier Reviews by Nuvectramedical - January 24th, 2021
- Medexus Submits Application to List on the Nasdaq - January 22nd, 2021
- XBiotech Candidate True Human™ COVID-19 Therapy Found to Target Highly Infectious Emerging Strain - January 22nd, 2021
- Unifor and Aleafia Health enter exclusive agreement to support medical cannabis coverage for members - January 22nd, 2021
- CorMedix Inc. to Begin Trading on the Nasdaq Stock Exchange - January 22nd, 2021
- Longboard Pharmaceuticals Appoints Brandi L. Roberts as Chief Financial Officer - January 22nd, 2021
- BetterLife Selects CRO to Conduct Clinical Trials for AP-003 in COVID-19 Cases in Indonesia - January 22nd, 2021
- Auxly Announces Upsized Bought-Deal Public Offering to $17.5 Million - January 22nd, 2021
- Trishula Therapeutics Appoints Anil Singhal as Chief Executive Officer - January 22nd, 2021
- Codiak’s Versatile engEx™ Platform for Engineered Exosomes Published in the Journal Molecular Therapy - January 22nd, 2021
- DEINOVE strengthens its Business development team to deploy its partnering strategy - January 22nd, 2021
- Hollister Biosciences Inc. Announces an Increase in Private Placement to $6.5 Million - January 22nd, 2021
- MDxHealth Launches Capital Increase and Provides Preliminary 2020 Financial Results - January 22nd, 2021
- MDxHealth Successfully Completes a EUR 25.0 Million (USD 30.4 Million)(1) Capital Increase - January 22nd, 2021
- Icosapent Ethyl Included in the Chinese Society of Cardiology (CSC) Updated Guidelines for Primary Prevention of Cardiovascular Diseases - January 22nd, 2021
- Bespoke Extracts Announces $100K Investment From CEO and Addition of New Brand Ambassador, UFC Fighter Maryna Moroz - January 22nd, 2021
- Nicox Analyst Coverage Initiated by Edison Investment Research - January 22nd, 2021
- Kiadis announces multiple abstracts related to its K-NK-cell therapy platform have been accepted for presentation at TCT, the Combined Transplantation... - January 22nd, 2021
- Immutep Quarterly Activities Report - January 22nd, 2021
- Ulcerative Colitis Phase II Study of GSK2831781 Discontinued - January 22nd, 2021
- ONO Receives a Manufacturing and Marketing Approval of Adlumiz® (Anamorelin), a Ghrelin Receptor Agonist for the Treatment of Cancer Cachexia in... - January 22nd, 2021
- Tarsus Pharmaceuticals, Inc. Appoints Bryan Wahl, MD, JD as General Counsel - January 19th, 2021
- Emerald Bioscience Launches Rebrand Including Name Change to Skye Bioscience - January 19th, 2021
- Iovance Biotherapeutics to Present at Upcoming Healthcare Conferences - January 19th, 2021
- NexImmune Appoints Healthcare Innovator Grant Verstandig as New Board Member - January 19th, 2021
- Capricor Therapeutics Announces Publication Demonstrating Methods for Enhanced Potency of Cardiosphere-Derived Exosomes - January 19th, 2021
- Bespoke Extracts Increases Conversion Price of Outstanding Discount Convertible Debentures - January 19th, 2021
- Neuropathix, Inc. Announces Publication of Its Global PCT Patent for NPTX-204, a Novel Hops-Inspired Neuroprotectant - January 19th, 2021
- Novan Provides Enrollment Update and Announces New Corporate Headquarters - January 19th, 2021
- Lixte Biotechnology and City of Hope to Initiate Phase 1b Clinical Trial of Lixte’s Lead Compound LB-100 to Treat Small Cell Lung Cancer - January 19th, 2021
- Tauriga Sciences Inc. to Construct Product Showroom Within its New Corporate Headquarters - January 19th, 2021
- Theratechnologies Announces Closing of US$46 Million Bought-Deal Public Offering, Including Full Exercise of the Over-Allotment Option - January 19th, 2021
- VIRBAC:2020 annual revenue shows strong growth of +5.7% at constant exchange rates and scope (+3.2% at constant rates) - January 19th, 2021
- Rafael Pharmaceuticals to Present at B. Riley Securities Virtual Oncology Investor Conference - January 19th, 2021
- Fulcrum Therapeutics Announces Promotion of Christopher Moxham, Ph.D., to Chief Scientific Officer - January 19th, 2021
- Agenus to Participate in B. Riley Securities' Oncology Investor Conference - January 19th, 2021
- Stockholders of BridgeBio Pharma, Inc. and Eidos Therapeutics, Inc. Approve BridgeBio Pharma, Inc. Acquisition of Eidos Therapeutics, Inc. - January 19th, 2021
- Histogen Reports FDA Clinical Hold for Planned Phase 1/2 Trial of HST-003 for Knee Cartilage Regeneration - January 19th, 2021
- Shockwave Medical to Report Fourth Quarter and Full Year 2020 Financial Results on February 17, 2021 - January 19th, 2021
- Eledon Pharmaceuticals to Participate in the Virtual Noble Capital Markets' Seventeenth Annual Investor / Equity Conference - January 19th, 2021
- Sorrento to Present Data Demonstrating STI-2020 Preserves Binding Against UK B.1.1.7 SARS-CoV-2 Mutated Spike Protein - January 19th, 2021
- Lexicon Pharmaceuticals Provides Regulatory Update on Sotagliflozin in Heart Failure - January 17th, 2021
- Artelo Biosciences Reports First Quarter Fiscal Year 2021 Financial Results and Provides Business Update - January 17th, 2021
- SELLAS Life Sciences Highlights 2020 Business and Clinical Progress and 2021 Milestones - January 17th, 2021
- PDS Biotech Releases White Paper Detailing the Potential of the Versamune® Platform in Overcoming a Major Limitation of Immuno-Oncology - January 17th, 2021
- Grey Cloak Tech Fuel4Thought™ Migraine Formula Results Published in World Journal of Advanced Research and Reviews - January 17th, 2021
- One World Pharma Receives Colombian Approval for Five THC Strains - January 17th, 2021
- Global Adoption of Biologicals Accelerates as Marrone Bio’s Grandevo® WDG Bioinsecticide is Approved for Use in New Zealand, Chile and on Hemp in... - January 17th, 2021
- RoosterBio Partners with Sartorius to Advance Cell and Gene Therapy Manufacturing - January 17th, 2021
- Theratechnologies to Present at the B. Riley Securities Virtual Oncology Investor Conference - January 17th, 2021
- Ceapro Inc. to Present at NobleCon17 - January 17th, 2021
- Tauriga Sciences Inc. Completes Payment for the Entirety of its Initial Production Run of its Caffeine Infused Version of Tauri-Gum - January 17th, 2021
- DBV Technologies Provides Update on Investigational Viaskin™ Peanut for Children Ages 4-11 Years - January 17th, 2021
- Dr. Han Myint Appointed as NextCure’s Chief Medical Officer - January 17th, 2021
- AIM ImmunoTech Reschedules Investor Conference Call to January 21, 2021 at 11AM ET - January 17th, 2021
- Global WholeHealth Partners, Corp (GWHP: OTC) Announces the Beginning Research for Saliva COVID 19 SARS 2 Antigen (N+S) Tests - January 17th, 2021
- Qilian International Holding Group Limited Announces Closing of Initial Public Offering - January 17th, 2021
- ERYTECH Announces First Patient Enrolled in a Phase 1 Investigator Sponsored Trial of Eryaspase in First-Line Pancreatic Cancer - January 17th, 2021
- Agios Presents Final Data from Phase 3 ClarIDHy Study of TIBSOVO® (ivosidenib tablets) in Patients with Previously Treated IDH1-Mutant... - January 17th, 2021
- TG Therapeutics to Participate in the B. Riley Securities Oncology Investor Conference - January 16th, 2021
- Manager’s transactions - January 16th, 2021
- VBL Therapeutics Enters Into Ordinary Share Purchase Agreement of up to $20 Million With Aspire Capital Fund, LLC - January 16th, 2021
- MediPharm Labs Appoints Warren Everitt, CEO Australia Pacific, to Board of Directors - January 16th, 2021
- Catalyst Biosciences Participating in a Fireside Chat with LifeSci Capital - January 16th, 2021
- Motus GI Announces European Clearance of Enhanced Pure-Vu® GEN2 System to Harmonize with U.S. Configuration - January 16th, 2021
- Regulatory Expert Henrietta Ukwu, M.D. Appointed Novavax Chief Regulatory and Quality Officer - January 16th, 2021
Recent Comments